Claims for Patent: 11,129,812

Summary for Patent: 11,129,812

Title:	Ophthalmic pharmaceutical compositions and uses relating thereto
Abstract:	The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
Inventor(s):	Feinbaum Claes, Salamun Franc, Patel Sudhir
Assignee:	ORASIS PHARMACEUTICALS LTD.
Application Number:	US16831535
Patent Claims:	2. The method of claim 1 , wherein the one or more stabilizers are selected from the group consisting of sodium hydrogen sulphite and/or ethylenediaminetetraacetic acids claim 1 , or mixtures thereof.3. The method of claim 1 , wherein the ophthalmic pharmaceutical composition is effective for up to 24 hours and/or effective without adversely affecting night vision.4. The method of claim 1 , wherein the administration is topical or by surgical intervention.5. The method of claim 1 , wherein the subject:a) is a spectacle wearer who cannot or will not use progressive or bifocal lenses;b) underwent cataract surgery;c) developed presbyopia after a corneal procedure;d) has mono-focal or multifocal intraocular lenses;e) uses contact lenses and does not tolerate mono-vision contact lenses;f) uses contact lenses and does not tolerate multifocal contact lenses;g) suffers from a higher order aberration after corneal surgery;h) suffers from hyperopia or tropias;i) does not tolerate a change in spectacle prescription;j) experiences a rapid change in spectacle prescription;k) is at risk of falls when using progressive or bifocal lenses; and/orl) suffers from a higher order aberration at night or under light conditions.6. The method of claim 1 , wherein the ophthalmic pharmaceutical composition is a slow release composition.7. The method of claim 1 , wherein the ophthalmic pharmaceutical composition is in the form of a suspension claim 1 , gel claim 1 , ointment claim 1 , injectable solution claim 1 , spray claim 1 , or eye drop formulation.8. The method of claim 7 , wherein the ophthalmic pharmaceutical composition is an eye drop formulation.9. The method of claim 1 , wherein the ophthalmic pharmaceutical composition is suitable for topical delivery to a subject's eye or tissue surrounding the eye.10. The method of claim 1 , wherein the ophthalmic pharmaceutical composition corrects presbyopia without adversely reducing visual field.11. The method of claim 3 , wherein the ophthalmic pharmaceutical composition is effective for up to 12 hours.12. The method of claim 11 , wherein the ophthalmic pharmaceutical composition is effective for up to 8 hours.